Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment.

Wierońska JM, Zorn SH, Doller D, Pilc A.

Pharmacol Ther. 2016 Jan;157:10-27. doi: 10.1016/j.pharmthera.2015.10.007. Epub 2015 Nov 5. Review.

PMID:
26549541
2.

The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.

Wierońska JM, Sławińska A, Łasoń-Tyburkiewicz M, Gruca P, Papp M, Zorn SH, Doller D, Kłeczek N, Noworyta-Sokołowska K, Gołembiowska K, Pilc A.

Psychopharmacology (Berl). 2015 Jan;232(1):259-73. doi: 10.1007/s00213-014-3657-4. Epub 2014 Jul 11.

3.

Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats.

Ossowska K, Wardas J, Berghauzen-Maciejewska K, Głowacka U, Kuter K, Pilc A, Zorn SH, Doller D.

Neuropharmacology. 2014 Aug;83:28-35. doi: 10.1016/j.neuropharm.2014.03.018. Epub 2014 Apr 12.

PMID:
24726309
4.

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Shahid M, Walker GB, Zorn SH, Wong EH.

J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28.

PMID:
18308814
5.

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH.

Eur J Pharmacol. 2001 Aug 17;425(3):197-201.

PMID:
11513838
6.

Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone.

Mansbach RS, Carver J, Zorn SH.

Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):535-42.

PMID:
11509214
7.

The pharmacology of weight gain with antipsychotics.

Casey DE, Zorn SH.

J Clin Psychiatry. 2001;62 Suppl 7:4-10. Review.

8.

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.

Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH.

Biol Psychiatry. 2000 Aug 1;48(3):229-37.

PMID:
10924666
9.
10.

Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.

Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Prete Di CC, Lee JS, Trozzi A.

Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30.

PMID:
9871530
11.

The discovery of potent and selective dopamine D4 receptor antagonists.

Faraci WS, Zorn SH, Sanner MA, Fliri A.

Curr Opin Chem Biol. 1998 Aug;2(4):535-40. Review.

PMID:
9736928
12.

Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition.

Mansbach RS, Brooks EW, Sanner MA, Zorn SH.

Psychopharmacology (Berl). 1998 Jan;135(2):194-200.

PMID:
9497025
13.

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.

Rollema H, Lu Y, Schmidt AW, Zorn SH.

Eur J Pharmacol. 1997 Nov 5;338(2):R3-5.

PMID:
9456005
14.

Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.

Fossa AA, DePasquale MJ, Morrone J, Zorn SH, Bryce D, Lowe JA, McLean S.

J Pharmacol Exp Ther. 1997 Apr;281(1):180-7.

15.

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

Howard HR, Lowe JA 3rd, Seeger TF, Seymour PA, Zorn SH, Maloney PR, Ewing FE, Newman ME, Schmidt AW, Furman JS, Robinson GL, Jackson E, Johnson C, Morrone J.

J Med Chem. 1996 Jan 5;39(1):143-8.

PMID:
8568801
16.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.

J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.

PMID:
7562537
17.

Clozapine is a potent and selective muscarinic M4 receptor agonist.

Zorn SH, Jones SB, Ward KM, Liston DR.

Eur J Pharmacol. 1994 Nov 15;269(3):R1-2.

PMID:
7895765
18.

Differential SAR of quinuclidine SP antagonists between rat and human-type receptors.

Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, Nagahisa A, Kanai Y, Suga O, Nakagaki M, Drozda SE, et al.

Regul Pept. 1993 Jul 2;46(1-2):290-2. No abstract available.

PMID:
7692519
19.

Discovery of CP-96,345 and its characterization in disease models involving substance P.

Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Jackson ER, Morrone J, McLean S, Bryce DK, Bordner J, et al.

Regul Pept. 1993 Jul 2;46(1-2):20-3. Review.

PMID:
7692490
20.
22.

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.

Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, McLean S, Bryce DK, Bordner J, et al.

J Med Chem. 1992 Jul 10;35(14):2591-600. Erratum in: J Med Chem 1992 Dec 11;35(25):4768.

PMID:
1378901
23.

Characterization in mammalian brain of a DARPP-32 serine kinase identical to casein kinase II.

Girault JA, Hemmings HC Jr, Zorn SH, Gustafson EL, Greengard P.

J Neurochem. 1990 Nov;55(5):1772-83.

PMID:
2145398
24.

Effects of reserpine on dopamine metabolite in the nucleus accumbens and locomotor activity in freely moving rats.

Sugita R, Sawa Y, Nomura S, Zorn SH, Yamauchi T.

Neurochem Res. 1989 Mar;14(3):267-70.

PMID:
2725828
25.

(R)-nipecotic acid ethyl ester: a direct-acting cholinergic agonist that displays greater efficacy at M2 than at M1 muscarinic receptors.

Zorn SH, Duman RS, Giachetti A, Micheletti R, Giraldo E, Krogsgaard-Larsen P, Enna SJ.

J Pharmacol Exp Ther. 1987 Jul;242(1):173-8.

PMID:
2886636
26.
27.
28.

GABA uptake inhibitors produce a greater antinociceptive response in the mouse tail-immersion assay than other types of GABAergic drugs.

Zorn SH, Enna SJ.

Life Sci. 1985 Nov 18;37(20):1901-12. Erratum in: Life Sci 1986 Feb 3;38(5):483.

PMID:
4058259

Supplemental Content

Support Center